HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Policy Update - The Official Results of 2020 Medical Insurance Negotiations

Presentation for Webinar: 2021 High Conviction-Investment Opportunities in China Healthcare Industry

Pre-IPO MicroPort CardioFlow - A Better Candidate of the TAVR Market in China?

2021 High Conviction - Investment Opportunities in China Healthcare Industry

Smartkarma North Asia Weekly: Alibaba Antitrust, OFAC Clarification, China Logistics, & Kuaishou IPO

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

1. Industry viewpoints:<ul>
<li>Last week, the National Healthcare Security Administration (NHSA) announced the results of 2020 medical insurance negotiations. </li>
<li>The negotiations results showed that all three domestic PD-1/L1 had successfully won the bidding to be included in the medical insurance.</li>
<li>Transdermal drug delivery systems (TDDS) is a hot research direction of improved new drugs, among which cataplasm has great development potential.</li>
</ul>2. Company news: News about the progress of new drugs and results of 2020 medical insurance negotiations from <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a> and <a href="https://www.smartkarma.com/entities/hutchison-china-meditech-ltd-7c2c4b58-ca71-4ac4-befb-345e8d0f10ca" target="_blank" data-smartkarma-citation="entities:27342:1" rel="noopener">Hutchison China MediTech Ltd (HCM US).</a>3. Market review:Last week, stock price for healthcare sector in A share increased 0.33%, while CSI 300 increased 3.36% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
Last week, the National Healthcare Security Administration (NHSA) announced the results of 2020 medical insurance negotiations. 
The negotiations results showed that all three domestic PD-1/L1 had successfully won the bidding to be included in the medical insurance.
Transdermal drug delivery systems (TDDS) is a hot research direction of improved new drugs, among which cataplasm has great development potential.
2. Company news: News about the progress of new drugs and results of 2020 medical insurance negotiations from Innovent Biologics Inc (1801 HK), Jiangsu Hengrui Medicine (600276 CH) and Hutchison China MediTech Ltd (HCM US).3. Market review:Last week, stock price for healthcare sector in A share increased 0.33%, while CSI 300 increased 3.36% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China Healthcare Weekly (Dec.31)